Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Icahn School of Medicine at Mount Sinai
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
68High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07059494CT.gov Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant | — | Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07543510CT.gov Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07461675CT.gov Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection | — | Not Yet Recruiting | — | — | — |
NCT07166406CT.gov Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | — | Recruiting | — | — | — |
NCT07363356CT.gov Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer | — | Not Yet Recruiting | — | — | — |
NCT07351513CT.gov A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07281664CT.gov Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT07317414CT.gov β-alanine in the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06680258CT.gov A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | — | Not Yet Recruiting | — | — | — |
Show 97 more trialsShow fewer
NCT07239245CT.gov Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo | — | Recruiting | — | — | — |
NCT06066138CT.gov A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | — | Recruiting | — | — | — |
NCT07018947CT.gov Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC | — | Not Yet Recruiting | — | — | — |
NCT07285850CT.gov The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD | — | Recruiting | — | — | — |
NCT07192185CT.gov Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab | — | Recruiting | — | — | — |
NCT06294548CT.gov A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | — | Recruiting | — | — | — |
NCT05690048CT.gov Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) | — | Recruiting | — | — | — |
NCT06971237CT.gov SIRT and Peri-immunotherapy : a New Concept | — | Not Yet Recruiting | — | — | — |
NCT06921785CT.gov Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06867432CT.gov Efficacy and Safety of Yttrium-90 Microspheres Selective Internal Radiotherapy Combined with Immune Checkpoint Inhibitors and Anti-angiogenesis Drugs Sequential HAIC for Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06789757CT.gov The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT07157969CT.gov ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | — | Recruiting | — | — | — |
NCT06695026CT.gov A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06725121CT.gov Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant | — | Recruiting | — | — | — |
NCT06584071CT.gov A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC | — | Not Yet Recruiting | — | — | — |
NCT06422403CT.gov A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | — | Recruiting | — | — | — |
NCT06618664CT.gov A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05733598CT.gov Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | — | Recruiting | — | — | — |
NCT06503250CT.gov A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization | — | Completed | — | — | — |
NCT06096779CT.gov A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | — | Recruiting | — | — | — |
NCT06478693CT.gov A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC | — | Recruiting | — | — | — |
NCT07293468CT.gov Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) | — | Recruiting | — | — | — |
NCT06339424CT.gov Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06109272CT.gov A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | — | Recruiting | — | — | — |
NCT05908786CT.gov A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT06117891CT.gov An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT06133062CT.gov Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05537402CT.gov LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC | — | Terminated | — | — | — |
NCT05904886CT.gov A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152) | — | Active Not Recruiting | — | — | — |
NCT05984511CT.gov TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | — | Recruiting | — | — | — |
NCT06006286CT.gov A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05908916CT.gov Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT05776875CT.gov Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | — | Terminated | — | — | — |
NCT05886465CT.gov HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | — | Unknown | — | — | — |
NCT05750030CT.gov FMT in IT-refractory HCC - FAB-HCC Pilot Study | — | Completed | — | — | — |
NCT05482516CT.gov Evaluating Novel Therapies in ctDNA Positive GI Cancers | — | Recruiting | — | — | — |
NCT05440708CT.gov A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05546879CT.gov Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC | — | Active Not Recruiting | — | — | — |
NCT05665348CT.gov Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy | — | Completed | — | — | — |
NCT05751343CT.gov Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial | — | Recruiting | — | — | — |
NCT05516628CT.gov Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05185505CT.gov Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | — | Recruiting | — | — | — |
NCT05448677CT.gov Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT05327738CT.gov Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05620771CT.gov Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk | — | Recruiting | — | — | — |
NCT05468359CT.gov Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | — | Recruiting | — | — | — |
NCT05377034CT.gov Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients | — | Recruiting | — | — | — |
NCT05992220CT.gov Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion | — | Recruiting | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05528952CT.gov Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05109052CT.gov Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT05488522CT.gov SBRT With Atezo/Bev for HCC | — | Recruiting | — | — | — |
NCT05096715CT.gov Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | — | Recruiting | — | — | — |
NCT05595473CT.gov A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT05168163CT.gov Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | — | Recruiting | — | — | — |
NCT05092373CT.gov Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | — | Recruiting | — | — | — |
NCT05359861CT.gov Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT07610551CT.gov Efficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05717738CT.gov Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT05396937CT.gov Efficacy and Safety of T+A+RAD in HCC | — | Unknown | — | — | — |
NCT04710641CT.gov Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone | — | Completed | — | — | — |
NCT05197504CT.gov Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy | — | Completed | — | — | — |
NCT04941287CT.gov Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | — | Active Not Recruiting | — | — | — |
NCT05093608CT.gov SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT04954339CT.gov DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab | — | Completed | — | — | — |
NCT05097911CT.gov Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | — | Active Not Recruiting | — | — | — |
NCT05173298CT.gov Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab | — | Unknown | — | — | — |
NCT04803994CT.gov The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma | — | Recruiting | — | — | — |
NCT04857684CT.gov SBRT + Atezolizumab + Bevacizumab in Resectable HCC | — | Active Not Recruiting | — | — | — |
NCT04563338CT.gov An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | — | Active Not Recruiting | — | — | — |
NCT05022927CT.gov A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04732286CT.gov A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy | — | Terminated | — | — | — |
NCT04862949CT.gov Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC | — | Completed | — | — | — |
NCT04770896CT.gov A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | — | Active Not Recruiting | — | — | — |
NCT04829383CT.gov A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04712643CT.gov A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma | — | Active Not Recruiting | — | — | — |
NCT04727307CT.gov Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial | — | Recruiting | — | — | — |
NCT04721132CT.gov Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT06323382CT.gov Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04541173CT.gov Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT07272265CT.gov The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study | — | Completed | — | — | — |
NCT04487067CT.gov A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | — | Completed | — | — | — |
NCT04224636CT.gov Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab | — | Recruiting | — | — | — |
NCT05713994CT.gov Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04180072CT.gov Atezolizumab Plus Bevacizumab With HCC and HBV Infection | — | Active Not Recruiting | — | — | — |
NCT04102098CT.gov A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | — | Completed | — | — | — |
NCT03942328CT.gov Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer | — | Recruiting | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03782207CT.gov A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | — | Active Not Recruiting | — | — | — |
NCT03829501CT.gov A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | — | Terminated | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03755791CT.gov Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | — | Active Not Recruiting | — | — | — |
NCT03434379CT.gov A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03232593CT.gov A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | — | Completed | — | — | — |
NCT03170960CT.gov Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02716012CT.gov First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | — | Unknown | — | — | — |
NCT02288507CT.gov Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Icahn School of Medicine at Mount Sinai | Approved | BB · 67 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →